A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)

被引：1
|
作者：
Hamilton, E. [1 ]
Loibl, S. [2 ]
Niikura, N. [3 ]
Rastogi, P. [4 ]
Saini, K. S. [5 ]
Gioni, I. [6 ]
Klinowska, T. [6 ]
Mayer, I. [7 ]
Stuart, M. [6 ]
Syta, E. [8 ]
Walding, A. [6 ]
Bachelot, T. [9 ]
机构：
[1] Sarah Cannon Res Inst Tennessee Oncol, Med Oncol Dept, Nashville, TN USA
[2] German Breast Grp GBG Forschungs GmbH, Med & Res Dept, Neu Isenburg, Germany
[3] Tokai Univ, Sch Med, Breast Oncol Dept, Isehara, Kanagawa, Japan
[4] Univ Pittsburgh, Oncol Dept, Pittsburgh, PA USA
[5] Fortrea Inc, Global Clin Dev, Durham, NC USA
[6] AstraZeneca, Late Dev Oncol R&D, Cambridge, England
[7] AstraZeneca, Late Dev Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca Canada Inc, Late Dev Oncol, Toronto, ON, Canada
[9] Ctr Leon Berard, Med Oncol Dept, Lyon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.3100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354TiP
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [41] The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early + /HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
    Keskinkilic, Merve
    Arayici, Mehmet Emin
    Basbinar, Yasemin
    Ellidokuz, Hulya
    Yavuzsen, Tugba
    Oztop, Ilhan
    BREAST, 2024, 78
  • [42] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [43] BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer.
    Gradishar, William John
    Bachelot, Thomas Denis
    Saletan, Stephen
    Graham, Anne Marie
    Rubini Liedke, Pedro Emanuel
    Azevedo, Sergio Jobim
    Sriuranpong, Virote
    Cardoso, Fatima
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
    Razavi, Pedram
    Ahmed, Mehnaj
    Roush, Ashley
    Parikh, Rohan
    Hitchens, Abigail
    Shen, Sherry
    Safonov, Anton
    Jhaveri, Komal L.
    Robson, Mark E.
    Peacock, Nancy Walker
    Ma, Yanjun
    Santarsiero, Elizabeth Chertow
    Ganapathy, Vaidyanathan
    Shah, Rohan M.
    Amefule, Adaeze Q.
    Lteif, Agnes
    Blakely, L. Johnetta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
    Hirshfield, Kim
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David
    McArthur, Heather
    Telli, Melinda
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Karantza, Vassiliki
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S288 - S288
  • [46] KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo plus neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (BC)
    Cardoso, F.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [47] Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study
    Jackisch, C.
    Stroyakovskiy, D.
    Muehlbauer, S.
    Heinzmann, D.
    Kopp, M. V.
    Ahn, J. S.
    Staroslawska, E.
    Falcon, S.
    Pivot, X.
    Ismael, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S37 - S37
  • [48] Standard-of-care Systemic Therapy with or without SBRT in Patients with oligoprogressive Breast Cancer or NSCLC ("CURB Oligoprogression"): an open-label, randomised, controlled, Phase 2 Study
    Stritzke, Florian
    Held, Thomas
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (09) : 850 - 852
  • [49] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
    Tolaney, Sara M.
    Fallowfield, Lesley
    Kaufman, Peter A.
    Ciruelos, Eva M.
    Gainford, Mary Corona
    Lu, Yi
    Hurt, Karla
    Wasserstrom, Heather Ann
    Chen, Yanyun
    Goel, Shom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study
    Wang, J.
    Xu, B.
    Cai, L.
    Song, Y.
    Kang, L.
    Sun, T.
    Teng, Y.
    Tong, Z.
    Li, H.
    Ouyang, Q.
    Cui, S.
    Yan, M.
    Chen, Q.
    Yin, Y.
    Sun, Q.
    Liao, N.
    Feng, J.
    Wang, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S461 - S462
12345